Senegal : In Senegal, the Covid-19 pandemic has revealed the urgency of developing the pharmaceutical industry. Yesterday, Monday, September 20, the recovery plan for this sector was unveiled by the ministers in charge of monitoring the PES and the Economy, Planning and Cooperation.
Good news for the 300 agents of Médis, the drug manufacturing plant. In a few days, the pharmaceutical plant, which is one of those which has been shut down, will resume its activities.
According to the national daily Le Soleil, which provided the information, the State of Senegal intends to invest 5.5 billion CFA francs in the capital of the company Médis, currently controlled by the Tunisian group of the same name.
>>> READ ALSO: Video. Senegal: Dr Malick Diop, expert in the pharmaceutical industry, reassures about the vaccine
Ultimately, Médis will have to produce 50% of the drugs consumed in Senegal. As a reminder, the staff of Médis remained 20 months without pay and no social support.
Senegal, which seems to have understood the importance of pharmaceutical self-sufficiency, has learned from covid-19 which has shown how important it is to locally produce the drugs that the country needs.
The Senegalese drug market represents some 150 billion CFA francs, 90% of which are imported, which constitutes a huge shortfall for the national economy.